DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via its interaction with the PDL1 ligand. Activation of PD1/PDL1 signaling has been suggested as a mechanism for tumors to invade an antigen-specific T-cell immunologic response in preclinical studies. Several immunomodulatory agents that target immune checkpoints are available. The FDA has approved PDL1 to treat…

AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States.  The UriFind® bladder cancer assay clinical trial in the United States, involving more than 1,000 patients across multiple centers, has officially begun patient enrollment, according to AnchorDx. In this perspective registrational study, the effectiveness of a non-invasive, quantitative real-time PCR (qPCR) assay developed to identify two DNA methylation biomarkers in urine…

Key Insights and Analysis Into the Point of Care Diagnostics Market

In recent years, the healthcare industry has witnessed immense growth in the screening and diagnostics segment. The incorporation of new-age technologies is bringing several life-saving revolutions to the market and improving the overall health outcomes for the patient. Digitization, innovation, newer hybrid business models, and the use of real-time health data and metrics are providing new insight and addressing various critical problems impacting the healthcare market. Similarly, point-of-care diagnostics (POCD) or point-of-care testing (POCT) is an evolving concept in healthcare and is gaining tremendous momentum and growth in demand. As…

Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lun...

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of…

Find out more
ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer ...

Lung Cancer presents a heavy health and economic burden in Asia, being the most common…

Find out more
Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Resul...

Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study  On November 22, 2022,…

Find out more
How is Technology Addressing the Sleeping Disorders?

Sleep disorders (or sleep-wake disorders) are one of the major health burdens in today's time.…

Find out more
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Arde...

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of…

Find out more
RNA Interference: New Class of Drugs In The Fight Against Disease

RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme…

Find out more
Artificial Intelligence (AI) in Mental Health
Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market

The clinical diagnostics market is highly competitive, with the active participation of numerous MedTech giants and regional players. Over the past few years, several key commercial and regulatory developments have immensely propelled the Clinical Diagnostics Market growth. However, there are a few challenges in the segment that are hampering the market growth

Find More
denovoskin-personalized-skin-graft
Can denovoSkin Be A Lifesaver for Burn Victims?

CUTISS' denovoSkin can be a gamechanger in the burns therapy segment. It holds the potential to change the treatment market dynamics.

Find More
Genital Warts
VP-102: A Potential Emerging Drug for Genital Warts

Genital Warts therapeutics market is expected to evolve immensely with the launch of emerging therapies, such as VP-102, and others

Find More
Generalized Anxiety Disorder
Psychedelic-inspired medicine – A wonder drug for generalized anxiety?

The launch of the psychedelic-inspired Generalized Anxiety Disorder treatment therapy is anticipated to transform the market scenario.

Find More
Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More
Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.